ARTICLE | Finance
Indexing pharma
Index gains GSK, J&J as LPs in dedicated life science fund
March 26, 2012 7:00 AM UTC
Index hopes that bringing on a pair of pharmas as anchor LPs in its newest fund will give the venture firm insight into which disease mechanisms to pursue and which to avoid.
Index last week announced the launch of its €150 million ($197.2 million) Index Life VI, the firm's first fund solely dedicated to life sciences. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the Johnson & Johnson Development Corp. venture capital unit of Johnson & Johnson(NYSE:JNJ) each contributed about 25%. The rest came from existing Index LPs...